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ORIGINAL ARTICLEShewanella algae infection in Italy: report of 3 years’ evaluation along the
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1) Unit of Microbiology, The Great Romagna Hub Laboratory, Pievesestina (FC), Italy and 2) DIMES, University of Bologna, Bologna, ItalyAbstractShewanella algae are Gram-negative, nonfermentative, motile bacilli, classified in the genus Shewanella in 1985. These environmental bacteria
are occasionally identified in human infections, with a relatively strong association with exposure to seawater during warm seasons. This
report describes a case series of 17 patients with infection correlated to S. algae in the coastal area of Romagna, Italy, from 2013 to
2016. The types of infection included otitis, pneumonia, sepsis and soft tissue (wound). Exposure to the marine environment during hot
months was confirmed in 12 of 17 patients. An apparent correlation between increased severity of infection and patient age was also
observed.
© 2018 The Authors. Published by Elsevier Ltd.
Keywords: Adriatic Sea, otitis, seawater, sepsis, Shewanella algae
Original Submission: 8 September 2017; Revised Submission: 29 December 2017; Accepted: 4 January 2018
Article published online: 12 March 2018Corresponding author: A. Torri, Unit of Microbiology, Great
Romagna Hub Laboratory, Piazza della Liberazione 60, edificio A,
47522, Pievesestina (FC), Italy.
E-mail: arianna.torri@auslromagna.it
The first two authors contributed equally to this article, and both
should be considered first author.IntroductionShewanella species are Gram-negative, nonfermentative, motile
bacilli. The first isolation occurred in 1931 by Derby and
Hammer from dairy products; they named this unknown spe-
cies Achromobacter putrefaciens [1]. In 1941, this species was
transferred to the genus Pseudomonas under the name
P. putrefaciens, and according to Shewan et al. [2], for the next
three decades, they were placed in the Pseudomonas IV group.
On the basis of phylogenetic studies and small subunit rDNA
sequencing, these organisms were reclassified to the Vibriona-
ceae family and described as a new genus, Shewanella. The genus
Shewanella was shown to be a monophyletic taxon within the
gamma subgroup of the phylum Proteobacteria. From 16S RNA
genetic analysis of genera belonging to this group emerged theThis is an open access artiexistence of a new family, Shewanellaceae, containing about 50
Shewanella spp., most of which are psychrophilic and therefore
of little interest to clinical microbiologists [3–5].
Bacteria of the genus Shewanella are found throughout the
world, mainly in marine environments and other underwater
settings; these germs have also been reported in soil, fish, meat,
poultry and dairy products [6]. Shewanella spp. are an unusual
cause of disease in humans; however, reports of Shewanella in-
fections have been increasing, likely as the result of better testing.
Most human Shewanella infections have been reported in warmer
areas, including Southeast Asia, Southern Europe, South Africa
and the Caribbean [7–10]. Sporadic cases have also been re-
ported from countries with cooler climates, including Australia,
Belgium and Denmark [10]. In Denmark, S. putrefaciens and S.
algae have been reported in seawater, with the frequency of
occurrence correlating with sea temperature. These organisms
were detected in Denmark only during July to October, when the
water temperature is above 13°C [11]. The only Shewanella spp.
found in human clinical specimens are S. putrefaciens and S. algae, and
more than80%of the isolates fromhumans reported in the literature
belong to S. algae [12–15]. Because these organisms are frequently
isolated together with other bacteria, the pathogenic potential of
Shewanella has been controversial since its very first report. In a
murine pathogenicity model, S. algae was the most virulent species,New Microbe and New Infect 2018; 23: 39–43
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could play an important role in its virulence factors [16].
The major risk factor linked to Shewanella infection is an
intimate association between humans and the marine environ-
ment or its contents; this correlation has been described in the
literature [11,17–22]. S. algae has also been isolated from the
heart of a dolphin with meningoencephalitis along the cost of the
Adriatic Sea; indeed, this is additional evidence of the potential
pathogenic role of S. algae for mammals in the marine environ-
ment [23]. The clinical picture of human infection caused by
S. algae is generally quite similar to those caused by various
species of the Vibrionaceae family: skin and soft tissue infections
associated with ulcers or trauma; ear infections present as acute
infections or acute exacerbations in chronic otitis media; and
bacteraemia, the course of which in S. algae blood infection is
usually benign [6]. To our knowledge, to date, only a single case of
isolation of S. putrefaciens has been described from Italy. This
event was related to a patient with soft tissue infection and
bacteraemia who, a few days before the infection, had just
returned from a holiday on the Adriatic shore [9].
This study was conducted to investigate the epidemiologic
and clinical characteristics of S. algae isolates obtained from
clinical specimens submitted for routine microbiologic diagnosis
over a period of 3 years (2013–2016) along the Romagna
Adriatic shore in northern Italy. To our knowledge, this is the
first report of human infection clearly caused by S. algae in Italy.Materials and methodsThe S. algae isolates were identified from samples routinely
submitted to the microbiology unit of the Great Romagna Hub
Laboratory, Pievesestina-Cesena, northern Italy. Details about
the standard diagnostic methods used to manage the samples
positive for S. algae isolates are provided online in Supplementary
Appendix S1. The identification of S. algae from the growing
brown mucous colonies was obtained (99% confidence) using a
VITEK MS instrument (bioMérieux, Marcy l’Etoile, France). The
antimicrobial susceptibility of S. algae isolates was determined
with a VITEK 2 system (bioMérieux). The Etest was used as a
confirmatory test for susceptibility to carbapenems and was
interpreted following European Committee on Antimicrobial
Susceptibility Testing (EUCAST) guidelines for other non-
Enterobacteriaceae glucose nonfermenting Gram-negative bacilli.ResultsFIG. 1. Seasonal trends of Shewanella algae isolates.
A total of 18 S. algae strains were isolated from 17 immuno-
competent patients seeking care at the healthcare facilities of© 2018 The Authors. Published by Elsevier Ltd, NMNI, 23, 39–43
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licethe Great Romagna area in northern Italy from 1 July 2013 to
30 November 2016. The Great Romagna area is located along
the coast of the western Adriatic Sea. The microbiology unit of
the Great Romagna Hub Laboratory serves the entire network
of these public facilities. All the isolates were found during April
to November, with a peak in July (Fig. 1). The S. algae strains
were identified in the following samples: blood cultures (n = 5),
skin and soft tissue swabs (n = 5), ear swabs (n = 5), bronchial
aspiration (n = 1) and sputum (n = 2). In one patient, S. algae
was isolated from two different types of specimens: blood
culture and bronchial aspiration.
Most patients with S. algae infection were older than 60
years (n = 12), with a mean age of 68 years. One patient was 43
years old, and the remaining four were children (mean age, 7
years and 6 months). Nine patients were female and eight were
male.
Recent (<4 weeks) exposure to seawater along the local
coast of the Adriatic Sea was reported for 13 patients. No
precise information is available in the scientific literature
regarding the incubation time of S. algae infections, and
consequently we can only hypothesize that for these 13 sub-
jects, the infection was a direct consequence of contact with
polluted seawater. All of the paediatric patients had otitis
externa. The adult patients had different clinical pictures: five
had skin and soft tissue infections, five had bacteraemia, two
had acute pneumonia and one had external otitis. It is note-
worthy that S. algae was associated with other pathogens in
nine of the 17 patients. All patients had a positive final outcome,
with the exception of a 92-year-old woman with sepsis, who
died 8 days after S. algae was cultured from a blood sample.
Table 1 summarizes the clinical picture of each patient.
All the S. algae isolates were susceptible to third-generation
cephalosporins and gentamycin. In addition, amikacin, carbape-
nems and piperacillin/tazobactam showed very good activitynses/by-nc-nd/4.0/).
TABLE 2. Antibiotic susceptibility of 17 strains of Shewanella
algae
Antibiotic
MIC (mg/L),
mean (range)
No. of clinically
sensitive isolates
of S. algae strains/no.
tested
Amikacin 2 (2 to 4) 15/17
NMNI Torri et al. Shewanella algae infection in Italy 41against most of the isolated strains. Amoxicillin/clavulanic acid
was efficacious against <50% of the isolates (5/13). Phosphomy-
cin showed no activity against the seven strains evaluated. The
in vitro activity of tigecycline and colistin was only evaluated
against five and six isolates, respectively. The antimicrobial sus-
ceptibility data of the 17 S. algae isolates are detailed in Table 2.
Amoxicillin/clavulanic acid 16 (2 to 32) 5/13
Cefepime 1 (1) 17/17
Cefotaxime 1 (1) 16/16
Ceftazidime 1 (1) 16/16
Ciprofloxacin 0.25 (0.25 to 2.0) 15/16Discussion
Phosphomycin 256 (256) 0/7
Gentamycin 1 (1) 17/17
Imipenem 1 (0.25 to 32) 14/17
Meropenem 1 (0.25 to 4.0) 16/17
Piperacillin/tazobactam 4 (4 to 128) 15/16
Tigecycline 0.5 (0.5) 5/5
MIC, minimum inhibitory concentration.Shewanella spp. infections have been reported worldwide. To
our knowledge, this is the first report of infections caused by
S. algae in Italy, where a single sporadic case of bacteraemia
associated with soft tissue infection by S. putrefaciens was
described 14 years ago [9]. The most frequent clinical features
of S. algae–related human disease include soft tissue infections,
otitis externa, invasive bacteraemia and sepsis with hepatic and
biliary involvement. Because Shewanella spp. are mostly envi-
ronmental microbes whose pathogenic mechanisms remain to
be completely elucidated, most cases of human infection
develop in people with underlying diseases, and infection is
often related to massive exposure to seawater [6].
Bacteria that today is included in the genus Shewanella were
first described in 1931 [1] as Achromobacter putrefaciens. Later
they were classified as P. putrefaciens, and finally the novel genus
Shewanella was proposed in 1985 [6]. The only Shewanella spp.
relevant for human diseases so far are S. putrefaciens and
S. algae, with a higher frequency of reported cases due to the
latter species. This potentially higher pathogenic capability for
humans has been correlated with the production of a haemo-
lysin [24]. Most automated identification systems based on
biochemical reactions are unable to distinguish between
S. putrefaciens and S. algae because the latter species is not
included in their database [7]. However, today, identification isTABLE 1. Clinical characteristics of 17 patients with Shewanella alg
Patient Age/sex
Additional microorganisms
isolated from same sample Clinical picture
1 6/F None Otitis externa
2 7/M Vibrio alginolyticus Otitis externa
3 8/F V. alginolyticus Otitis externa
4 9/F Klebsiella oxytoca Otitis externa
5 71/M None Otitis externa
6 83/M None Acute pneumonia
7 75/M None Acute pneumonia
8 80/M None Sepsis
9 92/F None Sepsis
10 82/F None Sepsis
11a 68/F None; Pseudomonas aeruginosa Sepsis; acute pneumo
12 78/M None Sepsis
13 70/F Staphylococcus aureus, Acinetobactecter
baumannii, Escherichia coli
Skin and soft tissue i
14 73/F Myroides spp. Skin and soft tissue i
15 65/F Staphylococcus aureus Skin and soft tissue i
16 66/M Morganella morganii Skin and soft tissue i
17 43/M None Skin and soft tissue i
aOnly patient from whom S. algae was isolated from two different samples (blood and bron
This is an open access articbased on matrix-assisted laser desorption/ionization time-of-
flight mass spectrometry, as these systems include the S. algae
spectrum in their database [25]. This new ability to correctly
and precisely identify S. algae has likely contributed to the
increased frequency of descriptions of infections caused by
S. algae in the last decade [26]. Our study describes a series of
17 cases of infection due to S. algae detected from 2013 to
2016 along the shores of northern Adriatic Sea in Romagna,
Italy.
As reported previously in other geographical areas, human
cases of S. algae infection are overwhelmingly linked with
exposure to the marine environment. The mode of contact
reported in the literature includes recreational or occupational
exposure, consumption of seafood, introduction of Shewanella
species into puncture wounds caused by marine life (sea ur-
chins, fish) or direct exposure to seawater. In our study, more
than 70% (12/17) of the patients reported massive contact with
seawater within 4 weeks of the isolation of S. algae. This fact
also correlates with the time period during which S. algae hasae infection
Exposure to seawater within 4 weeks Final outcome
Yes Positive
Yes Positive
Yes Positive
Yes Positive
Yes Positive
No Positive
Yes Positive
No Positive
No Died from acute sepsis
Yes Positive
nia Yes Positive
No Positive
nfection Yes Positive
nfection Yes Positive
nfection No Positive
nfection Yes Positive
nfection Yes Positive
chial aspiration).
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September), which corresponds to the months with the highest
frequency of sea-bathing activities along the coast of the
northern Adriatic Sea (Fig. 1). Because not all human cases of
infection by S. algae are linked to exposure to seawater, and
because other studies have not reported such a strong asso-
ciation, other possible ways to acquire this infection have been
hypothesized [6]. Such hypothetical modes of transmission
could also apply to the five patients in this series who did not
report contact with the marine environment. The presence of
S. algae in the marine environment correlates with water
temperature [10]. In the northern Adriatic Sea, the average
temperature is above 13°C from April until November, with a
peak (constantly above 20°C) from June to September detected
since 2011. This climatic feature is compatible with a possible
increase of S. algae concentration into seawater (http://www.
isprambiente.gov.it).
The isolation of S. algae was frequently associated with other
pathogenic or potentially pathogenic microbes (8/17 cases); this
was more relevant in cases of less invasive infection (3/5 otitis
externa, 4/5 wound infection) than in cases of bacteraemia or
acute pneumonia (1/6). This fact clearly suggests that in su-
perficial infections, the pathogenic role of S. algae is less defined
because the pathogen is part of a mixed infecting flora and is a
member of the microbiota found in the deeper part of skin and
soft tissue and wound infections. However, S. algae likely plays a
relevant pathogenic role on its own in invasive infections. As
previously described in a Danish study [12], S. algae causes
otitis, particularly in younger children, whereas invasive in-
fections apparently develop only in the older population. Most
of the cases of Shewanella-related bacteraemia are community
acquired [27,28], and in the absence of underlying complica-
tions, these infection have an overall benign clinical course
[28–30], as was indeed found in the population we studied. In
our cases series, only one patient died from sepsis due to
S. algae. This unfavourable outcome was correlated with the
extreme age (92 years) of the patient.
S. algae was also identified in specimens from infected
wounds; this is a common site for isolation of Shewanella spp.,
which are frequently found as members of the polymicrobial
flora in skin and soft tissue infections [10,21,22,30]. This
characteristic is likely linked to the exposure of broken skin to
environmental bacteria; in this limited cases series, four of five
patients with wound infections reported recent exposure to
the marine environment.
Acute pneumonia is infrequently caused by S. algae. Patients
can come into contact via the respiratory route in near-
drowning events in saltwater, via head submersion resulting
from recreational activities or via environmental exposure due© 2018 The Authors. Published by Elsevier Ltd, NMNI, 23, 39–43
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/liceto trauma [31]. In this study, only two strains were found as the
unique pathogen in sputum samples, thus confirming the rela-
tively infrequent role of S. algae in acute respiratory infections.
The in vitro antimicrobial susceptibility of S. algae was reviewed
in 2013 by Vignier et al. [10], who found that most isolates
were sensitive to third-generation cephalosporin, piperacillin/
tazobactam, ciprofloxacin and gentamycin. The isolates that we
evaluated showed almost identical patterns of antimicrobial
sensitivity. Erythromycin, chloramphenicol and tetracycline,
although reported in the literature as effective against S. algae
[10,28], were not included in our “Antimicrobial Susceptibility
Testing (AST)” evaluation because they do not belong the first
line of drugs used in clinical practice for the standard of cure for
the illnesses caused by S. algae. As reported in the literature,
S. algae showed a propensity towards resistance to carbape-
nems [30]. The mechanism of resistance may be related to a
carbapenem-hydrolyzing Amber class D β-lactamase [32]. This
feature was confirmed among the isolates described in this
study that were susceptible to imipenem (14/17 susceptible
isolates), with meropenem being more effective (16/17 sus-
ceptible isolates).
This study is novel in that it provides evidence for the first
time of the pathogenic role played by S. algae in Italy; in
particular, it confirms that isolation of this microbe mainly
occurs in patients exposed to the marine environment when
the seawater temperature is elevated. Although the number of
patients is small and we could therefore not perform statistical
analysis, we found an association between age and the severity
of the S. algae infection. Otitis was the predominant clinical
feature in children, whereas invasive infections and infections of
skin and soft tissue were prevalent in older subjects. Moreover,
the isolation of S. algae in clinical samples only during the
summer period correlates with data reported in the literature,
which demonstrate a connection between an increase in water
temperature and the frequency of identification of this organ-
ism in human infections. S. algae should be considered an
emerging opportunistic pathogen linked to environmental
conditions in the coastal area of Romagna.
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